This clinical trial is focused on studying the effects of a medication called semaglutide in people with a liver condition known as non-alcoholic steatohepatitis (NASH). NASH is a type of liver disease that occurs when fat builds up in the liver, leading to inflammation and damage. The study aims to see if semaglutide can improve liver health in people with NASH who have a certain level of liver scarring, known as fibrosis stage 2 or 3.
Participants in the study will receive either semaglutide or a placebo, which is a substance with no active medication. The treatment is given as an injection under the skin using a pre-filled pen. The study is divided into two parts. In the first part, researchers will look at whether semaglutide can improve liver tissue health over a period of 72 weeks. In the second part, they will assess if semaglutide can reduce the risk of liver-related health issues over a longer period of 240 weeks.
The study will monitor various health indicators, including changes in liver tissue, body weight, and other health markers, to determine the effectiveness of semaglutide. Participants will be followed up regularly to track their progress and any changes in their condition. The goal is to gather information on whether semaglutide can be a beneficial treatment for people with NASH, potentially improving their liver health and reducing the risk of further liver damage.
Austria 
Belgium 
Bulgaria 
Croatia 
Czechia 
Denmark 
France 
Germany 
Greece 
Ireland 
Italy 
Norway 
Poland 
Portugal 
Romania 
Slovakia 
Spain 
The Netherlands